Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "generics"

207 News Found

Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights


We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed
interviews | February 09, 2022

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India


Dr Reddy’s launch generic version of Vasostrict in the US
Drug Approval | February 09, 2022

Dr Reddy’s launch generic version of Vasostrict in the US

The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health


Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses


Dr. Reddy's set to acquire Nimbus Health
News | February 03, 2022

Dr. Reddy's set to acquire Nimbus Health

The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients


Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results


Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021